No injections
MacuMira does not involve needles or injections into the eye.
A noninvasive treatment option for people living with dry age-related macular degeneration.
MacuMira is a first-of-its-kind solution authorized by Health Canada to improve visual function in people living with dry age-related macular degeneration, also called dry AMD. It's safe, comfortable, and designed to fit easily into the clinical care experience.
At Capital Vision Care, MacuMira care begins with a detailed retinal assessment. Our optometrists review your diagnosis, symptoms, eye health, imaging and treatment goals to determine whether MacuMira may be appropriate for you.
Dry age-related macular degeneration affects the macula, the part of the retina responsible for sharp central vision. This is the vision you use for reading, recognizing faces, seeing road signs, watching television, using your phone and noticing fine details.
Dry AMD often develops slowly. In early stages, it may not cause obvious symptoms. As it progresses, central vision can become blurry, distorted, dim or less detailed, while side vision is usually less affected.
For many people, dry AMD has traditionally meant monitoring, lifestyle changes, vitamins when appropriate, and watching how vision changes. MacuMira offers a newer noninvasive option for patients diagnosed with dry AMD who want to explore whether treatment may help support their functional vision.

MacuMira is a noninvasive treatment for dry age-related macular degeneration. During treatment, a headset rests gently over your closed eyes and delivers low-level microcurrent stimulation through the eyelids. The goal is to stimulate retinal cells and support visual function in people with dry AMD. Results vary, and for appropriate patients it may help improve functional vision.
A short look at the MacuMira treatment and what to expect during a session.
You may want to ask about MacuMira if you have been diagnosed with dry age-related macular degeneration and notice changes such as:
MacuMira is not for every patient or every type of vision loss. A retinal assessment is needed first to determine whether it is appropriate.
MacuMira uses gentle microcurrent stimulation. Very low-level electrical energy is delivered through closed eyelids while you relax in the treatment chair.
MacuMira does not involve needles or injections into the eye.
There is no incision, surgical procedure or recovery period.
MacuMira is not a laser treatment.
MacuMira does not replace your eye care, supplements, glasses or medical treatment plan, and it does not require a new medication to complete.
Treatment sessions are completed in office, and most patients can return to their normal day afterward.
MacuMira is usually not a one-time treatment. Your optometrist will explain your recommended schedule and follow-up plan.
MacuMira treatment usually happens in two phases: an initial loading phase and an ongoing maintenance phase.
Each MacuMira session takes about 32 minutes. During treatment, you relax while the device delivers gentle microcurrent stimulation through your closed eyelids.
Many patients begin to notice changes during or shortly after this initial phase, although results vary.
After the loading phase, maintenance treatments are typically recommended about every 3 months to help maintain the visual gains achieved during the initial phase.
Your optometrist will recommend a schedule based on your dry AMD diagnosis, vision, retinal health, response to treatment and overall care plan. MacuMira is an ongoing treatment rather than a one-time fix, designed to support functional vision over time.
Your exact schedule may vary depending on your eyes and how your vision responds.
Before recommending MacuMira, your optometrist needs to understand your eyes, your diagnosis and your vision goals. Your assessment may include:
The goal is to determine whether your symptoms are consistent with dry AMD and whether MacuMira is a reasonable option for your situation.

MacuMira is available at all six Capital Vision Care clinics across Edmonton, St. Albert and Morinville. Book a consultation and we will confirm whether it is right for you.
Book a MacuMira ConsultationMacuMira is designed for dry age-related macular degeneration. Wet AMD requires urgent retinal assessment and may require specialist treatment such as injections.
MacuMira is noninvasive and authorized by Health Canada. There are no needles, surgery or lasers, and most patients find the treatment safe and comfortable.
Yes. A retinal and macular health assessment is needed to confirm whether MacuMira is appropriate and to rule out other causes of vision change.
MacuMira is a noninvasive treatment for dry age-related macular degeneration. It uses gentle microcurrent stimulation through closed eyelids to support retinal function and functional vision.
Dry AMD is a form of age-related macular degeneration that affects the macula, the part of the retina responsible for sharp central vision. It can make reading, recognizing faces, driving and seeing fine details more difficult.
Dry AMD usually progresses more gradually. Wet AMD involves abnormal blood vessels that can leak fluid or blood and may cause faster vision changes. Wet AMD requires urgent retinal care.
MacuMira may be appropriate for patients diagnosed with dry AMD who are experiencing visual impairment and want to explore a noninvasive treatment option. A retinal assessment is required first.
No. MacuMira is not a cure. It is a noninvasive treatment option that may help improve functional vision in appropriate dry AMD patients.
MacuMira is noninvasive. Some patients may feel mild tingling or notice patterns of light during treatment, but many find the session comfortable.
Each MacuMira treatment session is about 32 minutes. Your full appointment may be longer if testing, setup, imaging or consultation time is included.
Many patients report noticing vision changes during the first 10 days of treatment, but results vary. Your optometrist will monitor your response and explain what changes are meaningful for your condition.
MacuMira usually starts with a loading phase of 4 treatment sessions over the first 10 days. After that, maintenance treatments are typically recommended about every 3 months.
The loading phase is the first stage of treatment, a concentrated schedule of 4 sessions over approximately 10 days, designed to begin stimulating retinal function in patients with dry AMD.
The maintenance phase begins after the initial loading phase. Maintenance sessions are typically recommended about every 3 months to help maintain visual gains. Your optometrist will recommend the right schedule for your eyes.
No. MacuMira usually involves an initial loading phase followed by ongoing maintenance treatments to help support functional vision over time.
Your optometrist can advise you based on your AMD stage, health history and current care plan. MacuMira may be discussed alongside supplements, lifestyle changes and regular monitoring.
Coverage can vary. Ask our team about current pricing, private insurance, Health Spending Accounts and whether receipts may be used for medical expense claims.
Yes. MacuMira is available at all six Capital Vision Care clinics across Edmonton, St. Albert and Morinville.
If you have been diagnosed with dry age-related macular degeneration, MacuMira may offer a noninvasive option for supporting functional vision. Book a consultation at Capital Vision Care to find out whether it is appropriate for you.
Background on age-related macular degeneration and this treatment: